罕见病用药“最后一公里”梗阻 专项基金能否打通？

Core Viewpoint - The article emphasizes the urgent need for a comprehensive and sustainable support system for rare disease patients in China, highlighting the challenges they face in accessing necessary medications and treatments [1][10]. Policy Framework - The national policy framework for rare diseases is becoming clearer, with approximately 100 rare disease drugs included in the medical insurance directory by 2025, covering 42 disease types [2]. - Basic medical insurance is limited to addressing fundamental issues, indicating a need for a structured "second battlefield" to tackle high-value rare disease medications [2]. Patient Statistics - There are over 7,000 known rare diseases globally, affecting approximately 3.5% to 5.9% of the population, translating to 260 million to 450 million people worldwide [2]. - In China, around 1,400 rare diseases have been identified, with an estimated 20 million patients affected [2]. Case Study: Gaucher Disease - Gaucher disease serves as a key example of the challenges in medication access, with treatment costs reaching approximately 1 million RMB annually for patients [3]. - Shanghai has implemented a multi-channel support model since 2013, but the sustainability of this model is now in question due to potential discontinuation of funding [3]. Payment Models and Challenges - The DRG/DIP payment model creates financial disincentives for hospitals to treat rare disease patients, leading to a situation where patients struggle to access necessary care despite medications being covered by insurance [4]. - There are significant legal and systemic issues that need to be addressed to create a robust support system for rare disease medications and patient assistance [4]. Integration of Support Systems - The establishment of local rare disease special funds is seen as a necessary step to overcome fragmented policies and improve coordination among various support mechanisms [6]. - A comprehensive "1+N" model for rare disease support is emerging, integrating personal payments, special insurance, charitable donations, and national medical insurance [5]. Long-term Sustainability - Continuous medication is crucial for conditions like Gaucher disease, where treatment interruption can lead to irreversible damage, underscoring the need for stable and sustainable funding mechanisms [7]. - The proposed special funds aim to clarify application processes and share financial burdens among various support channels, addressing gaps in coverage for rare disease medications [7]. Local Initiatives - Local governments, such as Jiangsu Province, are developing provincial-level rare disease medication support mechanisms, which include specific diseases and treatment options [9]. - The Shanghai Rare Disease Relief Foundation has been instrumental in providing support and coordinating resources for patients, highlighting the importance of integrating various assistance programs [9]. Conclusion - The establishment of local rare disease special funds is not a rejection of existing systems but rather an enhancement of their capabilities, aiming to ensure that patients can access necessary medications and treatments consistently [10].